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Abstract 
The multifactorial complexity of spinal cord injuries includes the formation of a glial scar, of which chondroitin sulphated 
proteoglycans (CSPG) are an integral component. Previous studies have shown CSPG to have inhibitory effects on 
endothelial and neuronal cell growth, highlighting the difficulty of spinal cord regeneration. Mesenchymal stem/stromal 
cells (MSC) are widely used as a cell therapy, and there is mounting evidence for their angiogenic and neurotrophic 
paracrine properties. However, in vivo studies have observed poor engraftment and survival of MSC when injected into 
SCI. Currently, it is not known whether increasing CSPG concentrations seen after SCI may affect MSC; therefore we have 
investigated the effects of CSPG exposure to MSC in vitro. CSPG-mediated inhibition of MSC adhesion was observed 
when MSC were cultured on substrates of increasing CSPG concentration, however MSC viability was not affected even 
up to five days of culture. Culture conditioned medium harvested from these cultures (primed MSC CM) was used as 
both culture substrata and soluble medium for EA.hy926 endothelial cells and SH-SY5Y neuronal cells. MSC CM was 
angiogenic, promoting endothelial cell adhesion, proliferation and tubule formation. However, exposing MSC to CSPG 
reduced the effects of CSPG-primed MSC CM on endothelial cell adhesion and proliferation, but did not reduce MSC-
induced endothelial tubule formation. Primed MSC CM also promoted neuronal cell adhesion, which was reduced 
following exposure to CSPG. There were no marked differences in neurite outgrowth in MSC CM from CSPG primed MSC 
cultures versus control conditions, although non-primed MSC CM from the same donors was found to significantly 
enhance neurite outgrowth. Taken together, these studies demonstrate that MSC are resilient to CSPG exposure, but 
that there is a marked effect of CSPG on their paracrine regenerative activity. The findings increase our understanding of 
how the wound microenvironment after SCI can mitigate the beneficial effects of MSC transplantation. 
 
Introduction 
Mesenchymal stem/stromal cells (MSC) are routinely characterised using criteria released from the International Society 
of Cellular Therapy (ISCT), which includes plastic adherence, a specific CD marker profile and tri-lineage differentiation 
potential to form osteoblasts, chondrocytes and adipocytes [1,2]. Hence, MSC have been isolated and cultured from 
bone marrow and adipose tissue from a variety of species, including rodents, humans and dogs [3-6]. However, 
more recent studies have suggested that MSC have a wider function that simply acting as stem/progenitor cells for 
mesenchymal tissues and that they can elicit immunomodulatory and wound healing activity through paracrine 
activities on endogenous cells already present at sites of injury [7]. 
The potential of using MSC as a therapy for spinal cord injury (SCI) has been investigated using smaller animal 
models [5,6,8]. These studies, coupled with in vitro experiments, have provided evidence that transplanted MSC 
stimulate SCI repair through a number of mechanisms, including MSC-mediated secretion of sol uble neurotrophic 
and angiogenic growth factors, direct cell-cell contact and the deposition of MSC-secreted extracellular matrix 
components that can bridge the wound microenvironment to enhance axonal regeneration [4,7-11]. However, MSC 
survival has been found to decrease rapidly following their transplantation into SCI lesion sites [12-14], which limits 
their wound healing effects [13]. 
Currently, little is known as to which factors in the SCI lesion site may cause transplanted MSC numbers to decrease so 
quickly when used as a therapeutic. What is known is that the SCI lesion becomes an increasingly hostile 
microenvironment after injury wherein a combination of excitotoxicity, immune cell influx and the generation of a 
glial scar, which is formed by reactive astrocytes secreting chondroitin sulphated proteoglycans (CSPG), prevents tissue 
repair [15-17]. The glial scar, in particular, is a major block to SCI repair mechanisms because although it provides a 
 
mechanism to limit the damage caused by SCI and hence prevent further damage to the blood-spinal cord barrier 
(BSCB), the CSPG present within the scar inhibits sufficient axonal regeneration [15,17]. 
After SCI, CSPG concentrations within the glial scar increase over time, reaching peak concentrations at 2 weeks post 
injury [18,19]. Furthermore, studies observing decreased MSC viability in vivo after SCI, reported reduced viability as 
early as 2 weeks following transplantation [12-14]. This temporal coincidence of an increase in CSPG levels with 
decreased MSC survival raises the possibility that the formation of the glial scar may contribute, at least in part, to how 
successful MSC transplantation may prove. Nonetheless, even with the decline in MSC numbers post graft, beneficial 
actions of MSC transplantation have still been observed [13,14]. Furthermore, in vitro studies of MSC culture conditioned 
medium have also reported angiogenic and neurotrophic effects [4,9,10,20], strengthening theories that the reparative 
activities of MSC in SCI derive from the MSC secretome. Enhancing angiogenesis is especially important during the 
recovery stages of SCI, as blood vessels are the system of delivery for nutrients and oxygen, as well as the removal of 
waste products. Following ischaemia, angiogenesis can also reduce secondary damage to axons [21,22]. 
To our knowledge, no studies have examined whether CSPG influence MSC viability or MSC-mediated wound healing 
activity. Therefore, this study has used in vitro techniques and established cell reporter assays [4,11] to establish both 
the effects of CSPG on MSC viability and also on MSC-mediated angiogenic and neuro- trophic paracrine activity. 
 
Materials and methods 
 
MSC isolation and growth 
Institutional ethical approval was obtained for this study (University of Chester: 060/16/CW/BS, 18th May 2016). After 
consent, samples of adipose tissue were surgically extracted from inguinal fat pads of dogs (n = 3 donors) 
undergoing MSC transplantation treatments of joint pathology. MSC were isolated via collagenase digestion and 
preferential plastic adhesion, as described previously [3,4], and subsequently cultured in Dulbecco's modified Eagle 
medium/F-12 GlutaMAX™ (DMEM/F-12), supplemented with 1% penicillin/streptomycin (P/S) and 10% foetal bovine 
serum (FBS) (standard culture medium) (all Gibco®, Life Technologies™, Paisley, UK) in a humidified atmosphere of 5% 
CO2 at 37 C. Routine passaging was completed when cultures reached 80% confluences using 0.25% trypsin-EDTA 
(Gibco®, Life Technologies™). The culture-expanded cells were characterised for plastic adherence, 
immunophenotyped and assessed for tri-lineage differentiation potential, as we have reported recently [4], and 
hence shown to exhibit an MSC phenotype. 
 
Culturing MSC on CSPG and the generation of CSPG-primed MSC conditioned medium 
6 well culture plates were incubated with solution of 0 µg/ml, 10 µg/ml or 100 µg/ml chondroitin sulphated 
proteoglycans (CSPG1; Sigma Aldrich, Dorset, UK) at 4° C overnight to allow CSPG adherence to the culture plastic. CSPG-
coated wells were washed three times with Dulbecco's phosphate buffered saline (PBS, Gibco®, Life 
Technologies™), completely aspirated and the plate warmed for a minimum of 1 h at 37° C/5% CO2 to allow the wells 
to completely dry. MSC were then seeded into the wells at a density of 1.8 105 cells/well in 10 ml of serum-free 
conditioning medium (DMEM/F12 supplemented with ITS+, NEAA and penicillin/streptomycin, all Gibco®, Life 
Technologies™). The plate was incubated at 37° C/5% CO2 for a total of 5 days after which time the culture- 
conditioned medium (MSC CM) was harvested, filtered through a 0.20 µm filter to remove any cell debris, and stored 
at 20° C for further experimentation. Control medium was generated by incubating the same volume of serum-free 
medium used to culture MSC at 37° C for 120 h and then harvesting in the same manner as each of the MSC CM. In 
some experiments, MSC CM was generated separately by seeding MSC into T75 flasks in DMEM/F12 medium 
supplemented with 10% fetal bovine serum and antibiotics, as reported previously [4]. 
During the MSC culture on CSPG-coated substrata, the cells were imaged digitally under phase contrast microscopy at 2h, 
 
24 h and 120 h post seeding. The proportion of MSC that appeared adherent, as delineated by the presence of cell 
processes extending onto the culture surface, versus non-adherent (no visible cell processes and a spherical cell 
morphology) was determined scoring a minimum of 50 cells for each condition and each MSC tested. MSC viability was 
assessed by phase contrast microscopy and further by incubating MSC seeded into CSPG-coated substrata in Live/Dead 
staining solution, wherein calcein AM stains viable cells with green fluorescence and propidium iodide stains non-viable 
cells with red fluorescence, following the manufacturer's instructions (Live/Dead Cell Double Staining Kit, 04511, Sigma 
Ltd). The proportion of cells that were green (live) or red (dead) when viewed under fluorescence microscopy (490 nm) 
was scored and digitised images collected using a GX-CAM HiChrome-S camera. 
 
EA.hy926 endothelial cell and SH-SY5Y neuronal cell adhesion assays 
The effects of MSC CM on EA.hy926 endothelial cell and SH- SY5Y neuronal cell adhesion was assessed by MTS assay 
[23,24] as follows: briefly, 96 well tissue culture plates were coated with 50 ml of MSC CM versus control medium 
overnight at 4° C, followed by washes in PBS (as described above for CSPG coating), prior to seeding with EA.hy926 or SH-
SY5Y cells at a density of 5 x 103 cells in 100 ml of serum-free medium per well (triplicate wells for each MSC CM). After 
2 h of incubation at 37° C/5% CO2, wells were washed to remove non-adherent cells and 100 ml serum-free medium plus 
20 ml of MTS solution (Promega CellTiter 96® AQueous One Solution Cell Proliferation Assay, Promega, Southampton, 
UK) added to each well and the plate was incubated for a further 2 h at 37° C/5% CO2. Absorbance was measured at 
490nm (iMark micro-plate reader, Bio-Rad, Kidlington, UK). Cells were also imaged digitally under phase contrast 
microscopy. 
 
EA.hy926 endothelial and SH-SY5Y neuronal cell proliferation assays 
The effects of MSC CM on EA.hy926 endothelial cell and SH- SY5Y neuronal cell proliferation was assessed by culturing 
cells in MSC CM versus control medium and then performing MTS assays to determine the relative numbers of 
metabolically active cells, as described previously [4]. In brief, EA.hy926 or SH-SY5Y cells were seeded into 96 well 
plates at a density of 5 x 103 cells per well in 100 ml of standard serum supplemented culture medium and 
incubated for 24 h at 37° C/5% CO2 to permit cell adherence. Then the serum supplemented culture medium was 
removed and wells were washed twice with 50 ml of serum-free medium prior to the addition of 100 ml of MSC 
CM or control medium (n = 3), and incubated at 37° C/5% CO2. After 48 (endothelial cell assays) and 72 (neuronal cell 
assays) hours, 20 ml of MTS solution was added directly to wells and absorbance measured using a 
spectrophotometer, as described above. Cells were also imaged digitally under phase contrast microscopy. 
 
Matrigel assays for EA.hy926 endothelial tubule formation 
The effects of MSC CM versus control medium on the formation of endothelial tubule-like structures were assessed 
using the Matrigel assay, as described previously [4,25]. Briefly, Matrigel™ (Corning, New York, USA) was used to coat 96 
well plates (100ml/well) for 30 min at 37° C/5% CO2 and then seeded with EA.hy926 cells at a density of 2 x 104 cells per 
well in 200 ml of MSC CM or control medium and incubated at 37° C/5% CO2 for 24 h. The plate was then loaded into the 
Cell-IQ imaging system (Chipman Technologies, Tampere, Finland) under x10 magnification and digitised images 
analysed for tubule formation using the Cell-IQ imaging software. 
 
SH-SY5Y neurite outgrowth assays 
SH-SY5Y neuronal cells were seeded into a 24 well plate at a density of 1 x 104 cells per well in 1 ml of standard serum 
sup- plemented culture medium and incubated for 24 h at 37° C/5% CO2 to permit cell adherence. After this period, the 
culture medium was removed, the wells were washed with serum-free medium and then 1 ml of MSC CM or control 
 
medium added prior to incubation at 37° C/5% CO2 for 72 h. At 72 h post-treatment, digitised images were collected 




At least 3 independent experiments were performed, i.e. using MSC and MSC CM generated from 3 separate tissue 
donors. IBM SPSS software was used for statistical analyses. Data generated from n = 3 MSC donors was pooled and 
tested for normal distribution using the Shapiro-Wilk test and then relationships between parameters and differences 
between groups were tested for significance using either a one way analysis of variance (ANOVA) with Tukeys post-hoc or 
T-tests for normally distributed data or a Kruskal-Wallis test with Mann Whitney U tests post-hoc for non-normally 





CSPG substrata inhibited MSC adhesion, but did not affect MSC viability 
Using CSPG to coat wells as a culture substratum inhibited MSC adhesion in a concentration-dependent manner (Fig. 1). 
Hence, at 2 h post-seeding, the MSC morphology, i.e., a more stromal appearance with cytoplasmic extensions onto 
the culture surface and the extent of cell spreading indicated a greater adhesion in control wells compared with 
reduced adhesion as the coating concentration of CSPG increased. This evident inhibition of MSC adhesion by CSPG 
coating was also seen at 24 h post-cell seeding, but by 120 h post-seeding there was no apparent difference in the 
morphology of MSC on all culture substrata. Image analyses of digitised images collected throughout time course 
demonstrated that both proportions of adherent versus non-adherent MSC and the extent of MSC spreading were 
significantly inhibited by CSPG coated in such a transient manner (Fig. 1B). However, MSC appeared phase bright at 
all time, indicating viable cultures, and Live/Dead staining at 24 and 120 h post-seeding demonstrated that culturing 
MSC on increasing CSPG concentrations had little to no effect on their viability (Fig. 1A: inset). The lowest MSC 
viability recorded was 98 ± 1% viable cells at 24 h post-seeding and 96 ± 3% viable cells at 120 h post-seeding. 
 
Culturing MSC on CSPG-coated substrata reduced the pro-adhesive and proliferative effects of primed MSC CM on 
EA.hy926 endothelial cells with little effect on the formation of endothelial tubule-like structures 
MSC CM generated from MSC cultured on 0 µg/ml and 10 µg/ml CSPG-coated substrata significantly increased EA.hy926 
endothelial cell adhesion after 2 h of culture compared to control medium. However, there was a marked reduction in 
this pro-adhesive effect from MSC CM generated from MSC cultures on 100 µg/ml CSPG-coated substrata (Fig. 2). 
Similarly, MSC CM from MSC cultured on 0 µg/ml and 10 µg/ml CSPG-coated substrata increased EA.hy926 endothelial 
cell proliferation at 48 h of treatment compared to control medium, which also was not seen using MSC CM from 100 
µg/ml CSPG-coated substrata (Fig. 3). Conversely, the effects of SC CM in enhancing the formation of tubule-like 
structures by EA.hy926 cells on Matrigel were not diminished by prior priming of the MSC CM through CSPG exposure (Fig. 
4). There was a significant increase in EA.hy926 endothelial tubule formation when the endothelial cells were cultured in 
MSC CM harvested from 0 µg/ml, 10 µg/ml and 100 µg/ml CSPG coated wells (all  p < 0.05; Mann- Whitney U test) 
compared to control medium. 
 
Culturing MSC on CSPG-coated substrata reduced the pro-adhesive effects of primed MSC CM on SH-SY5Y neuronal 
 
cells with little effect on SH-SY5Y neurite outgrowth 
MSC CM generated from MSC cultured on 0 µg/ml, 10 µg/ml and 100 µg/ml CSPG-coated substrata significantly 
increased SH-SY5Y neuronal cell proliferation after 72 h of culture compared to control medium. However, there was a 
marked reduction in this pro-adhesive effect from MSC CM generated from MSC cultures on 100 µg/ml CSPG-coated 
substrata (Fig. 5). Conversely, none of the CSPG primed MSC CM, including the conditioned medium generated from 
MSC cultures that had been seeded onto PBS-only coated wells (0 µg/ml primed MSC CM) enhanced SH-SY5Y neurite 
outgrowth compared to control medium (Fig. 6). We previously observed that MSC CM harvested from MSC 
cultures seeded in T75 flasks in serum-supplemented medium to initially permit cell adhesion then washed and 
cultured in serum-free medium enhanced SH-SY5Y neurite outgrowth [4]. Therefore, in separate experiments using 
MSC from the same donors that have been used in the current study we generated MSC CM using the technique 
previously reported. Similar to our previous results, we found that this MSC CM was neurotrophic, significantly 
enhancing SY-SY5Y neurite outgrowth compared to control medium (Fig. 6C). 
 
Discussion 
Following SCI, the combination of inflammatory cytokines, widespread cell death and immune cell influx causes 
surviving local astrocytes to become reactive. These reactive cells secrete CSPG, which, along with debris from dying cells 
and myelin sheath degradation, form the glial scar [16]. Although perhaps the primary action of the glial scar is to aid in 
restoration of the BSCB, so limiting further CNS damage, the CSPG present is inhibitory to new nerve growth [15,17]. 
Hence, the presence of CSPG in the damaged spinal cord is a major consideration to strategies that target axonal 
regeneration and spinal cord repair. 
Transplanting MSC directly into SCI lesion sites in animal models increases functional recovery, which is thought to be 
mediated by the secretion of factors by the transplanted MSC [9,20]. However, the viability of MSC decreases 
dramatically within weeks of transplantation, limiting their wound healing capacity [12-14]. The causes of MSC death 
following transplant could be due to the severe microenvironment within the injured area of the spinal cord [12-14]. 
As described above, the accumulation of a CSPG-rich matrix in the SCI lesion is one aspect of this 
microenvironment. Therefore, this study has examined whether exposing MSC to CSPG has any effect on their growth 
and viability, as well as their capacity to stimulate angiogenesis and nerve growth, both of which are integral to SCI 
repair processes. We used these concentrations of CSPG specifically because previous research has shown that 
EA.hy926 endothelial cell migration [26] and SH-SY5Y neurite outgrowth [27] were not inhibited at 10 µg/ml CSPG, 
but were inhibited at 100 µg/ml CSPG. Increased CSPG is thought to an important role in inhibiting CNS repair [18,19] 
and although the exact CSPG concentrations seen in vivo after SCI are not well documented, the range that we 
have examined includes those levels of CSPG that have little/no effect on endothelial cells and nerve growth and 
those that are inhibitory, at least in vitro. Hence, the range was intended to mimic those levels that may be seen in 
the CNS lesions into which MSC have been transplanted. 
Our data shows that MSC adhesion was transiently inhibited by CSPG-coated substrata, as has been reported previously 
for a variety of other cell types including neurons and endothelial cells [9,10,28-30]. However, the MSC became 
adherent and more spread on the CSPG-coated substrata with time, which may indicate either that CSPG was being lost 
from the substrata, possibly due to MSC-mediated degradation [31-33], or that the MSC were secreting other 
adhesive ECM, e.g. collagens, laminin or fibronectin [20], which masked the CSPG. Further experimentation is 
required to determine how MSC adhesion to the CSPG substrata increased with time. However, exposure to CSPG did 
not significantly affect MSC viability at any time point during this study. Hence, our results do not support the 
hypothesis that increased levels of CSPG seen in the glial scar play a direct role in reducing the numbers of viable MSC 
after their transplantation, suggesting that other microenvironmental factors may be responsible for this cell loss. 
In contrast, exposure of the MSC to CSPG reduced the extent to which the MSC secretome, in the form of MSC CM, 
promoted some aspects of angiogenesis. Similar to previous reports [11], MSC CM generated from MSC cultures that 
had not been exposed to CSPG enhanced EA.hy926 endothelial cell adhesion (when used as a MSC CM-coated culture 
 
substratum) and EA.hy926 endothelial cell proliferation (when used as a soluble culture medium) compared to control 
medium. However, priming the MSC through CSPG expo sure reduced this adhesive and proliferative effect in a 
CSPG concentration-dependent manner. Using Matrigel assays [4,25], MSC CM was also found to enhance 
EA.hy926 endothelial tubule formation compared to control medium; however, this proangiogenic effect was not 
significantly changed by CSPG priming. Therefore, from this data it can be concluded: (i) MSC secreted proangiogenic 
factors; (ii) MSC exposure to CSPG reduced their pro- adhesive and proliferative effects on endothelial cells. This suggests 
that the presence of CSPG altered the MSC phenotype, at least in terms of angiogenic activity, and raises the important 
question as to how this change may have arisen it if wasn't associated with decreased MSC viability. Previous 
research has suggested that as MSC differentiate to form chondrocytes, they have reduced angiogenic activity [34]. 
Furthermore, changes in MSC morphology to a more spherical cell shape compared to a flattened, fibroblastic 
shape, is associated with increased chondrogenesis [35]. Hence, one possibility may be that the transient changes 
seen in MSC morphology when their adhesion to the CSPG-coated substrata was inhibited also may have reduced their 
secretion of angiogenic factors, e.g. decreased vascular endothelial growth factor (VEGF) expression, or increased 
their secretion of anti-angiogenic factors, e.g. CSPG [11]. In addition, if CSPG are released from the culture substrata as 
a result of MSC culture, then the fact that CSPG itself inhibits endothelial cell adhesion and migration [26,36] suggests 
that this may also play a role. Further research is required to address these questions, which may have direct relevance 
to the impact that transplanted MSC have in the SCI milieu. 
MSC CM was found to promote SH-SY5Y neuronal adhesion when used as an MSC CM-coated culture substratum, an 
effect that was diminished by MSC culture on high concentrations of CSPG. This suggests that the MSC CM contained 
molecules that are pro- adhesive to neuronal and endothelial cells (as discussed above, e.g. collagen, laminin and 
fibronectin), which we have previously reported is present in the MSC secretome [11]. The presence of ECM 
components that support neuronal and endothelial cell adhesion can be related to increased nerve growth [37] as 
well as angiogenesis [38]. However, and contrary to our previous research [4], the MSC CM generated in this study 
had no effect on SH-SY5Y neurite outgrowth. To examine whether the method of MSC CM generation used in the 
current study could have accounted for this difference in outcome from our previous research, we also made MSC 
CM using our previously published methods [4] and found that this harvested conditioned medium was neurotrophic. 
Further research is required, therefore, to better understand this difference in outcome and fully establish the effects of 
exposing MSC to CSPG on their neurotrophic activity. The MSC CM generated in the current protocol was harvested after 
a 5 day culture period, whereas our previous protocol was harvested after only a 3 day culture period. This extra time in 
culture may have caused a shift in the levels of secretome components. Like all cells, MSC require growth factors and 
nutrients to survive [39] and to synthesise proteins [40]. Hence, the MSC used in this study may have started to reduce 
their secretion of trophic factors and re-uptake products that had been secreted over the first 3 days of culture to 
counter decreasing growth factor/nutrient levels. This could have reduced the level of some secretome components 
within the MSC CM, possibly even differentially, e.g. MSC possess the low affinity nerve growth factor receptor CD271 
[41] hence there may have been potentially increased NGF uptake with time, which in terms would mean less 
neurotrophic activity within the MSC CM. The results from this study suggest that there may be more complex 
interactions between MSC, MSC-secreted factors, CSPG exposure and time in culture, and this warrants further 
investigation. 
Finally, it is noteworthy that these findings have relevance to other CNS disorders, not just SCI, where stem cell 
transplantation has shown great potential. These include the use of different potentially therapeutic cells, including 
MSC, to combat stroke and traumatic brain injury [42-46]. The survival of the transplanted cells and the effects of CSPG 
on their wound healing activity may well play an important role in these scenarios. 
 
Conclusions 
In conclusion, exposing MSC to CSPG prior to harvesting culture conditioned medium, possibly with a view to using MSC 
CM therapeutically in SCI, has shown a variety of interesting effects that need further investigation. CSPG priming of 
MSC CM reduced its trophic effects on endothelial cell adhesion and proliferation, and moderately inhibited some 
 
aspects of neurogenesis (i.e. neuronal cell adhesion), but not neurite outgrowth. This reduction in trophic activity may 
influence important aspects of MSC-mediated SCI repair by limiting new blood vessel formation and nerve growth. 
Proteomic study of the MSC CM generated in these conditions in future research may give further insight as to how 
CSPG interactions in the SCI microenvironment influence repair processes. This knowledge could help the design of 
more effective ways of culturing MSC to enhance the MSC-mediated wound healing activity. 
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